EUCTR2005-002316-24-DE进行中（未招募）不适用
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.
Takeda Europe R &D Centre Ltd0 个研究点目标入组 400 人开始时间: 2005年10月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male and female subjects aged = 18 years
- •- Capable of understanding and willing to sign the Informed Consent Form
- •- Documented diagnosis of Type 2 diabetes mellitus for > 6 months (Random venous plasma glucose = 200mg/dL (11.1 mmol/L), 2-hour glucose tolerance during a 75g oral glucose tolerance testing (OGTT) = 200mg/dL or Fasting Plasma Glucose (FPG) > 126 mg/dL (7 mmol/L)), with stable glycaemic control over a period of at least 3 month and Hb A1c of 9.5 % or less
- •- On a stable antidiabetic regime, which may include oral antidiabetic medication and/or insulin, for at least 3 months prior to Screening (Visit 1)
- •- The most recent value of LDL-c = 100 mg/dL (2.59 mmol/L) and triglycerides = 400 mg/dL (4.52 mmol/L ), within the previous 6 months, currently treated with one of the following lipid-lowering drugs: atorvastatin (10 mg, 20 mg, or 40 mg), simvastatin (20 mg or 40 mg), rosuvastatin (10 mg or 20 mg), or fenofibrate (not to exceed 200 mg daily), and no changes in the medication for at least 4 Weeks before Screening (Visit 1). If no value is available, then confirm acceptability for enrolment from result on sample taken at screening visit 1.
- •- The subject is otherwise in good health as determined by a physician (ie, via medical history and physical examination)
- •- At Randomisation (Visit 4) in order to be randomised subjects must have fulfilled the above criteria and also have: Mean LDL-cholesterol levels of = 100 mg/dL (2.59 mmol/L) and mean triglycerides level of = 400 mg/dl (4.52 mmol/L). The mean values will be calculated from measurements made at Week –2 (Visit 2) and Week –1 (Visit 3) for each subject. For LDL-cholesterol the difference between the two individual values must not differ by more than 15% of the upper value. For triglycerides the upper value for either sample must be =450 mg/dL (5.1 mmol/L). If the inclusion range is not attained for either LDL-c or triglycerides levels then the investigator will repeat these assessments at an additional Visit (Visit 3.1). If the LDL-c and triglycerides level then fulfil the above criteria at two consecutive visits, at least 1 week apart, and the individual value at Visit 3.1 compared to one individual value from Visit 2 or 3 does not differ by more than 15%, then the subject may enter the active phase of treatment with TAK-475 100 mg or placebo
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •At Screening (Visit 1) and at Randomisation (Visit 4) or when specified below, the subjects must not be/have:
- •- Type 1 Diabetes Mellitus
- •- Between screening and randomisation:
- •(i) ALT or AST level > 1.5 times the upper limit of normal (ULN)
- •(ii) Serum creatinine > 133 µmol/L (>1.5 mg/dL) or
- •(iii) CPK > 3 times the upper limit of normal (ULN).
- •Active liver disease, gallbladder disease (with or without cholelthiasis) or jaundice .
- •- Positive hepatitis B surface antigen, or hepatitis C virus antibody, as determined by medical history and/or subject’s verbal report.
- •- Positive human immunodeficiency virus status or is taking retroviral medications, as determined by medical history and/or subject’s verbal report.
- •- Known hypersensitivity or history of adverse reaction to TAK-475
- •- Unable or unwilling to discontinue excluded medications or to continue stable doses of stable dose medications or would require treatment with any excluded medication during the study.
研究者
相似试验
进行中（未招募）
1 期
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.treatment of patients with primary dyslipidaemiaMedDRA version: 8Level: ptClassification code 10058108EUCTR2005-002316-24-SKTakeda Global R &D Centre (Europe)400
进行中（未招募）
不适用
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.treatment of patients with primary dyslipidaemiaMedDRA version: 8Level: ptClassification code 10058108EUCTR2005-002316-24-LVTakeda Europe R &D Centre Ltd400
进行中（未招募）
不适用
A study to see how effective and safe the drug Kappaproct is in patients with refractory ulcerative colitis when added to their standard care of treatmentChronic active treatment refractory ulcerative colitisMedDRA version: 16.1Level: PTClassification code 10009900Term: Colitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-003130-14-CZInDex Pharmaceuticals AB120
进行中（未招募）
不适用
Clinical Trial to assess the efficacy and safety of KappaproctChronic active treatment refractory ulcerative colitisMedDRA version: 14.1Level: PTClassification code 10009900Term: Colitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-003130-14-ITINDEX PHARMACEUTICALS132
进行中（未招募）
1 期
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.treatment of patients with primary dyslipidaemiaMedDRA version: 8Level: ptClassification code 10058108EUCTR2005-002316-24-DKTakeda Europe R &D Centre Ltd400